Last deal
Amount
Stage
Date
all rounds
date founded
Financing round
General
About Company
Industry
Sector :
Subsector :
founded date
founders
Number of employees
Company Type
Last funding type
IPO status
Contacts
Similar Companies1000
KSQ Therapeutics
KSQ Therapeutics pioneers High-Confidence Drug Development using CRISPRomics technology.
Sector
Subsector
Location
total rounds
total raised
Tegmine Therapeutics
Tegmine Therapeutics develops antibody-based therapeutics targeting proteins and their disease-related glycan modifications.
Sector
Subsector
Keywords
Location
total rounds
Biolexis Therapeutics
Biolexis Therapeutics is a company that uses its FIELDS™ technology to rapidly develop new drugs and accelerate the drug discovery process.
Sector
Subsector
Location
total rounds
total raised
NextRNA Therapeutics
NextRNA Therapeutics discovers targeted therapeutics by identifying and modulating RNA binding proteins responsible for disease..
Sector
Subsector
Keywords
Location
total rounds
total raised
Financials
Funding Rounds1
Number of Funding Rounds
Their latest funding was raised on 25.05.2017. Their latest investor IndieBio. Their latest round Seed
IndieBio
IndieBio is a biotechnology and life science startup accelerator that focuses on solving global problems using biology.
Sector
Subsector
Location
total rounds
total raised
count Of Investments
count Of Exists
SOSV
SOSV is a global venture capital firm that supports early-stage startups.
Sector
Subsector
Keywords
Location
count Of Investments
count Of Exists
Co-Investors
Investors2
Number of lead investors
Number of investors
IndieBio
IndieBio is a biotechnology and life science startup accelerator that focuses on solving global problems using biology.
Sector
Subsector
Location
total rounds
total raised
count Of Investments
count Of Exists
SOSV
SOSV is a global venture capital firm that supports early-stage startups.
Sector
Subsector
Keywords
Location
count Of Investments
count Of Exists
Arvind Gupta
Arvind Gupta co-leads Mayfield’s Engineering Biology practice. He was the first investor in breakout bio companies such as Geltor, Synthex, Prime Roots, NotCo, Prellis, New Culture, DNA Lite and Memphis Meats. As Founder of IndieBio, Arvind redefined the pace and possibilities of early stage biotech, investing in over 136 companies in five years, defining human and planetary health, and growing the IndieBio portfolio into billions of dollars in value. Under his leadership, IndieBio expanded to New York and grew to fifteen investment professionals with a world class adjunct partner board. He is now Venture Advisor at IndieBio. Arvind is the author of Decoding the World: A Roadmap for the Questioner, published by Twelve Books, a division of the Hachette Publishing Group. He was honored with the F50 Global Award for Impact in HealthTech Innovation. He is a frequent speaker at TechCrunch Disrupt, Slush, TedX and Future FoodTech. His work has been profiled in global media outlets such as Bloomberg News, Forbes, The Guardian UK, Neo.life, Nikkei News, Rotman, The Times of India, and CGTN in China. Arvind has been a guest lecturer at UCSF, MIT and Harvard and is a judge at the annual BIO conference startup stadium. Prior to founding IndieBio, Arvind was Design Director at IDEO in Shanghai where he earned numerous international design awards and presented his work at the San Francisco Museum of Modern Art. Arvind received his B.S. in Genetic Engineering from UCSB. He holds 8 patents. Arvind is married to an Icelander and has two daughters.
current job
organization founded
People
Founders2
Michael Anstey
Michael Anstey is an Investment Director specialising in healthcare investments. Before joining CIC he was a Principal in the Healthcare Practice Area at The Boston Consulting Group’s (BCG) Toronto office. Michael has experience in advising multinational healthcare businesses across North America, Europe, India, and Japan on a broad range of topics, including corporate strategy, sales and marketing, new launches, R&D and medical strategy, and M&A. Michael was co-founder and COO of an early stage biotechnology company focused on developing small molecule drugs that target protein-protein interactions implicated in disease. Prior to BCG, Michael worked in venture capital, where he focused on investing in early stage healthcare and life science businesses. Michael earned his DPhil in Zoology in the field of neurobiology, jointly supervised by professors at the University of Cambridge and the University of Oxford. Michael sits on the board of Bicycle Therapeutics.
current job
organization founded
Michael Anstey
Aman Iqbal
Aman Iqbal is the Founding Partner of Vantage Health.
current job
organization founded
Aman Iqbal
Employee Profiles3
Michael Anstey
Co-Founder and Chief Operating Officer